For the Inventor, By the Inventor

Enter assignee name

Watertown, MA, United States of America

C4 Therapeutics, Inc.

USPTO Granted Patents = 32

EPO Patents = 4

Trademarks = 9

Forward Citations = 168

Loading Chart...

Loading Chart...

47 inventors (with patents filed for the assignee):

Christopher G Nasveschuk (21 out of 58 patents)

Yanke Liang (18 out of 40 patents)

James A Henderson (16 out of 24 patents)

4. Andrew John Phillips (16 out of 46 patents)

5. Minsheng He (13 out of 24 patents)

6. Kiel Lazarski (11 out of 23 patents)

7. Ryan E Michael (9 out of 9 patents)

8. Annick Goergler (9 out of 23 patents)

9. Fabian Dey (8 out of 25 patents)

10. Martin Duplessis (8 out of 28 patents)

11. Roger David Norcross (8 out of 92 patents)

12. Gesine Kerstin Veits (7 out of 7 patents)

13. Eric Andre Kusznir (6 out of 6 patents)

14. Mark E Fitzgerald (5 out of 5 patents)

15. Katrina L Jackson (5 out of 5 patents)

32 patents: Sort by Forward Citations

1. 12486290 - Isoindolinone and indazole compounds for the degradation of EGFR (2025-12-02),

2. 12486253 - Therapeutics for the degradation of mutant BRAF (2025-12-02),

3. 12454521 - Targeted protein degradation (2025-10-28),

4. 12441740 - N/O-linked degrons and degronimers for protein degradation (2025-10-14),

5. 12421220 - Bicyclic-substituted glutarimide cereblon binders (2025-09-23),

6. 12371442 - Isoindolinone and indazole compounds for the degradation of EGFR (2025-07-29),

7. 12365681 - Dihydrobenzimidazolones for medical treatment (2025-07-22),

8. 12180225 - N/O-linked degrons and degronimers for protein degradation (2024-12-31),

9. 12157735 - Compounds for targeted degradation of BRD9 (2024-12-03),

10. 12091397 - Dihydroquinolinones for medical treatment (2024-09-17),

11. 12076405 - Heterocyclic degronimers for target protein degradation (2024-09-03),

12. 12049464 - Compounds for targeted degradation of BRD9 (2024-07-30),

13. 12048748 - Spirocyclic degronimers for target protein degradation (2024-07-30),

14. 12048747 - Substituted piperidine Degronimers for Target Protein degradation (2024-07-30),

15. 11992531 - C-carbon linked glutarimide degronimers for target protein degradation (2024-05-28),

C4 Therapeutics, Inc. is a biotechnology company focused on developing targeted protein degradation therapeutics. Their approach uses small molecules to tag proteins for degradation, offering potential treatments for a broad range of diseases, including cancer and neurodegenerative disorders.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

32 Patents

#12 in Watertown, MA

#607 in Massachusetts

#10,227 in US

#20,053 in the World

Watertown, MA, United States of America

C4 Therapeutics, Inc.

Forward Citations = 168

47 inventors:

Christopher G Nasveschuk (21 out of 58 patents)

Yanke Liang (18 out of 40 patents)

James A Henderson (16 out of 24 patents)

4. Andrew John Phillips (16 out of 46 patents)

5. Minsheng He (13 out of 24 patents)

Please report any incorrect information to support@idiyas.com

Loading…